[A20-99] Ivacaftor (cystic fibrosis, 4 to < 6 months, with R117H mutation) - Benefit assessment according to §35a Social Code Book V
Last updated 01.03.2021
Commission awarded on 27.11.2020 by the Federal Joint Committee (G-BA).
Airways and respiratory system
Patients with cystic fibrosis from 4 to < 6 months of age and weighing 5 kg or more who have an R117H mutation in the CFTR gene
Added benefit not proven.
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.